Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer

Plain-language summary

This study aims to develop laboratory models (xenografts) from surgically removed tumor samples of patients with triple negative or Luminal B breast cancer, collecting blood samples for this purpose. It is enrolling adult women with histologically confirmed triple negative or Luminal B breast cancer. The study is a non-phased study and is still recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Recruiting

Sponsor

Centre Jean Perrin

Intervention

blood samples collection

Start date

11/19/2021

Estimated completion

8/31/2030

Countries

France

Related genes

Locations

• Clermont-Ferrand, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2
* Signature of the participation consent to the study,
* Affiliation to a social security scheme
* Major woman with:

  * metastatic triple-negative (TN) breast cancer, histologically proven before treatment and high grade, receiving neoadjuvant chemotherapy and having, after treatment, a breast residue of at least 15 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of neoadjuvant treatment
  * metaplastic triple-negative (TN) breast cancer, histologically proven before treatment and high grade, treated by primary surgery with a tumor size of at least 15 mm on the specimen.
  * an inflammatory TN breast cancer (T4d), histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a breast residue of at least 15 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of the neoadjuvant treatment.
  * non-metaplastic or inflammatory TN breast cancer, histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a mammary residue of at least 30 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of the neoadjuvant treatment.
  * Luminal B breast cancer (LB), histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a mammary residue of at least 30 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of the neoadjuvant treatment.
  * histologically proven metastatic TN or metastatic breast cancer with an operable metastasis whose residual size, after chemotherapy, is at least 10 mm on the specimen. Residual metastasis will be at least 15 mm on imaging.
* Patients in a metastatic situation can be included regardless of the therapeutic line.

Exclusion Criteria:

* Pregnant woman
* Patient deprived of liberty by court or administrative decision
* In neoadjuvant situation: no neoadjuvant treatment by radiotherapy or hormone therapy
* Refusal to participate in the study